Can a dual immunotherapy erase hidden myeloma cells?

This phase 3 trial tests whether combining two immunotherapies, teclistamab and talquetamab, can eliminate residual cancer cells in multiple myeloma patients who have undergone a stem cell transplant. Participants with detectable minimal residual disease (MRD) are randomly assigned to receive either the new combination or standard maintenance therapy with daratumumab and lenalidomide. The main goal is to see if more patients achieve undetectable MRD with a complete response after 12 months, which could reduce the risk of relapse and improve long-term outcomes.